Palatin Technologies (PTN) Accumulated Expenses (2011 - 2026)
Palatin Technologies' (PTN) quarterly Accumulated Expenses came in at $653397.0 in Q1 2026, up 29.01% YoY from $506460.0 in Q1 2025, and down 0.98% on a QoQ basis from $659841.0 in Q4 2025.
Palatin Technologies (PTN) Accumulated Expenses (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 15 years of Accumulated Expenses data on file, last reported at $653397.0 in Q1 2026.
- Quarterly Accumulated Expenses rose 29.01% year-over-year to $653397.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $653397.0 (up 29.01% YoY) and the FY2025 annual result came in at $881412.0, down 78.94% from the prior year.
- Accumulated Expenses fell to $653397.0 in Q1 2026, from $659841.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $7.2 million in Q3 2023 to a low of $506460.0 in Q1 2025.
- A 5-year average of $3.7 million and a median of $4.2 million in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2023 — Accumulated Expenses soared 74.34% — and 2025, when it plunged 85.13%.
- Tracing PTN's Accumulated Expenses over 5 years: stood at $6.1 million in 2022, then dropped by 7.44% to $5.6 million in 2023, then plunged by 70.6% to $1.7 million in 2024, then tumbled by 60.03% to $659841.0 in 2025, then decreased by 0.98% to $653397.0 in 2026.
- The last three Accumulated Expenses figures came in at $653397.0 (Q1 2026), $659841.0 (Q4 2025), and $679966.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 653,397.00 |
| Dec 31, 2025 | 659,841.00 |
| Sep 30, 2025 | 679,966.00 |
| Jun 30, 2025 | 881,412.00 |
| Mar 31, 2025 | 506,460.00 |
| Dec 31, 2024 | 1.65 Mn |
| Sep 30, 2024 | 4.57 Mn |
| Jun 30, 2024 | 4.19 Mn |
| Mar 31, 2024 | 2.36 Mn |
| Dec 31, 2023 | 5.61 Mn |
| Sep 30, 2023 | 7.15 Mn |
| Jun 30, 2023 | 6.51 Mn |
| Mar 31, 2023 | 5.54 Mn |
| Dec 31, 2022 | 6.07 Mn |
| Sep 30, 2022 | 6.12 Mn |
| Jun 30, 2022 | 6.88 Mn |
| Mar 31, 2022 | 3.18 Mn |
| Dec 31, 2021 | 6.18 Mn |
| Sep 30, 2021 | 4.99 Mn |
| Jun 30, 2021 | 5.80 Mn |